GemVax und KAEL geben Ergebnisse der klinischen Phase-2a-Studie zu PSP bekannt
South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a clinical trial evaluating a drug for PSP. While the drug failed to show significant efficacy, the results showed enough promise that the company is proceeding to phase 3 trials. PSP, or progressive supranuclear palsy, is an FTD disorder…
WeiterlesenLiebe HelpLine: Reiseplanung während der Feiertage
Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with FTD 2 years ago. Is there anything you can share with me about traveling with someone with FTD? For many people, the holiday season is…
WeiterlesenEin Gespräch mit dem Vizepräsidenten für klinische Entwicklung bei Alector
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to address FTD caused by a variant in the GRN gene. The special designation enables expedited regulatory review of therapies intended to treat serious conditions. A…
WeiterlesenVesper Bio gibt erfolgreichen Abschluss der Phase-1-Studie zur potenziell krankheitsmodifizierenden Behandlung von FTD-GRN bekannt
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the trial demonstrated excellent safety and tolerability of the orally administered drug VES001. In FTD caused by an inherited GRN mutation, the production of the essential…
Weiterlesen24. November 2024: Persönliches Meet & Greet in Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. The event will take place from 7:30 a.m. – 12:00 p.m. on November 24 at St. Catherine of Siena…
WeiterlesenPersönliches Meet & Greet in Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. RSVP for this event by emailing sgordon@theaftd.org. To learn more, download this flyer.
WeiterlesenOhio Hybrid Caregiver Lunch and Learn: Frontotemporale Demenz
Bring a lunch and join Judy Bearer, ambassador for the Association for Frontotemporal Degeneration, for this lunch and learn event about frontotemporal degeneration (FTD), the most common cause of dementia in adults under 60 (though it can strike adults at any age). We will review possible causes and symptoms, find local resources, and learn how…
WeiterlesenAFTD-Webinar: Diagnose der primären progressiven Aphasie
With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive enough to prompt further assessment by a specialist. This webinar is intended for clinicians to support early detection and accurate diagnosis of PPA. Learners will…
WeiterlesenSagen Sie es Ihren Gesetzgebern: Bewilligen Sie die Finanzierung des Older Americans Act erneut
You may think that because frontotemporal degeneration strikes many people in the middle of their life, that the Older Americans Act may not apply to you. But the OAA provides funding for services for adult family members and other adults who care for individuals with Alzheimer’s disease and related disorders in their home, regardless of…
WeiterlesenAdvancing Hope: AFTD veranstaltet FTD-Forschungs-Roundtable-Meeting 2024
The FTD Research Roundtable is an annual program designed to accelerate FTD drug development by convening various scientific stakeholders to identify common challenges and advance solutions for FTD clinical trials. Biopharmaceutical companies currently conducting FTD pre-clinical and clinical trials are invited to join the FTD Research Roundtable, and in 2024, we were thrilled to have…
Weiterlesen
German 
English 
Spanish (Mexico) 
French 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)